Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · REKVINA LABORATORIES LTD. · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
REKVINA LABORATORIES LTD.
BSE: 526075
BSE: 526075
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
REKVINA LABORATORIES LTD.
StateQ1 FY27 filed
Last close · 20 Sept 2026₹53.84
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA94.5 · — · —
REKVINA LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1 |
| EBITDA (ex other income) | (0) | (0) | (0) | (0) | (0) |
| margin % | — | — | — | — | (20.1) |
| Owners' profit | (0) | (0) | (0) | (0) | (0) |
| EPS, as reported (₹) | (0.13) | (0.00) | 0.00 | 0.22 | 0.42 |
| ROE % · ROCE % | (563.6) · (539.3) | (5.3) · (2.3) | 515.6 · 515.6 | 40.5 · (631.8) | 20.7 · 20.7 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | (0.75) | (1.20) |
| Cash from operations | (0) | 0 | (0) | (0) | (1) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · REKVINA LABORATORIES LTD. · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| Net profit | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| EPS (₹) | 0.11 | 0.04 | 0.07 | 0.00 | 0.06 | 0.21 | 0.10 | 0.20 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 94.5 | 29.6 | 154 of 170 | 10% |
| ROCE | 20.7 | 10.8 | 32 of 183 | 83% |
| ROE | 20.7 | 10.4 | 20 of 171 | 89% |
| Debt / Equity | (1.2) | 0.1 | 4 of 171 | 98% |
| EBITDA margin | (18.0) | 17.5 | 162 of 165 | 2% |
| Profit growth | (240.4) | 30.9 | 150 of 158 | 5% |
| Market cap | 32 | 770 | 159 of 184 | 14% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · REKVINA LABORATORIES LTD. · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 12 Sept 2026 · MD and Director Amit Shah resigns from Rekvina Labs effective Sept 11, 2026 | management changes | high | — | — |
| 3 Sept 2026 · FY26 Annual Report approved, AGM on Sep 29, CS resigns | management changes | medium | — | — |
| 3 Sept 2026 · 38th AGM on Sep 29 via video conferencing; 2 new independent directors | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Company Secretary resigns at Rekvina Laboratories | management changes | medium | — | — |
| 18 Aug 2026 · Promoters raise stake in Rekvina Labs to 60.30% via preferential allotment and open offer | ownership changes | high | — | — |
| 17 Aug 2026 · Rekvina Labs: Non-promoter acquirer crosses 10% holding via open offer and preferential allotment | ownership changes | medium | — | — |
| 13 Aug 2026 · Rekvina Labs Q1 loss widens to Rs 12L; Surbhit Shah named Chairman | management changes | high | — | — |
| 13 Aug 2026 · Board Approves Q1 Results, Surbhit Shah Named Chairman | management changes | high | — | — |
| 12 Aug 2026 · Allots 50.87 lakh shares on preferential basis for Radiant Parenterals acquisition | fund raising | high | — | — |
| 1 Aug 2026 · Board Meeting on 13 Aug 2026 to Approve Q1 FY26 Results | results | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in